Dear Eli Lilly Stock Fans, Mark October 29 on Your Calendar Eli Lilly’s weight-loss boom faces fierce competition, but its next earnings report could reveal why the best may still be ahead. Barchart · Oct 26
Thyroid Eye Disease Patients Gain First At-Home Injection Option as FDA Clears Roche's Enspryng for Adults The FDA approved Roche's Enspryng for thyroid eye disease, the first treatment patients or caregivers can inject at home every four weeks. Medical Daily · Oct 20
Why pharma giant Roche is putting German investments on hold Germany’s bid to revive its struggling economy faces a fresh setback as a major pharmaceutical player raises concerns over the country’s business climate. Euronews · Oct 20
Roche Bets Up to $1.16 Billion on Rona's Obesity Drug That Aims to Cut Fat but Spare Muscle Roche licensed Rona's experimental ALK7 obesity drug in a deal worth up to $1.16 billion. No human data are out yet. What it means for weight loss. Medical Daily · Oct 15
Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech's patent infringement suit, the New Jersey court dismissed the… The Economic Times · Oct 15
Manufacturing Site Problems, Not Trial Results, Push Back FDA Decision on Novo's Once-Monthly Hemophilia A Drug Denecimig FDA's review of Novo's hemophilia A drug denecimig is delayed by manufacturing site issues, not trial data. Launch is now targeted for 2027. Medical Daily · Oct 5
Lancet Publishes Full Petrelintide Trial: About 10% Weight Loss, Nausea in 20% as Amylin Drug Enters Phase 3 Full Phase 2 results for petrelintide in The Lancet show about 10% weight loss and nausea in 20%. What the experimental amylin drug means for patients. Medical Daily · Oct 1
Roche's Enicepatide Cut Blood Sugar and Weight in Type 2 Diabetes Trial, but Placebo Figures Were Not Released Roche says enicepatide cut HbA1c by 2.65 points and weight by 15.5% in a phase 2 diabetes trial, but placebo data were not released. Here is what the results show. Medical Daily · Sep 23
European drugmakers say they are ‘losing ground’ to US and Chinese rivals Some of continent’s biggest pharma firms write to national leaders calling for action to safeguard the sector The Guardian - UK · Sep 22
Alzheimer’s drug to be offered to people without symptoms in bid to prevent onset of disease The trial will give the drug Trontinemab to those at high risk of Alzheimer’s to see if the disease can be delayed or prevented The Independent UK · Sep 5
FDA Clears Roche Blood Test That Can Rule Alzheimer's Amyloid In or Out Without a Brain Scan FDA cleared Roche's Elecsys pTau217 blood test for adults 55 and older with cognitive symptoms. What it can and cannot tell patients. Medical Daily · Aug 25
ECB head Christine Lagarde 'ready to serve' WEF, report says The World Economic Forum is currently co-chaired by BlackRock CEO Larry Fink and André Hoffmann, the vice chairman of Roche. Euronews · Aug 23
Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized mRNA treatments as rivals including BioNTech and Roche pursue similar approaches. International Business Times · Aug 21
Do Teenagers On Isotretinoin Actually Understand The Risks They’re Signing Off On? For many teenagers, this acne medication is life-changing. For a small number of users, however, it brings something they never expected: depression and panic. The debate over whether patients are being warned properly has never really gone away. While most finish treatment without severe psychiatric problems, some users say the… Bored Panda · Jul 27
The Guardian - AU · Jul 16 Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved? Health minister Mark Butler confirms Ocrevus, Kesimpta and Lemtrada will stay subsidised amid questions about the Pharmaceutical Benefits Scheme
Medical Daily · Jun 19 FDA Approves First Generic Baloxavir (Xofluza): Single-Dose Flu Treatment Now Available at Generic Price FDA approved the first generic baloxavir marboxil (Xofluza) on June 17, 2026. Norwich Pharmaceuticals developed the single-dose flu treatment for patients 5 and older.
The Economic Times · Jun 15 Global drugmakers rush to boost US presence as tariff threat looms Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…
Fortune · Jun 12 Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls The proposed 10 million person limit could ruin Switzerland’s reputation as a business hub and risks harming one of Europe’s strongest economies, business leaders warn.
MarketBeat · Jun 11 Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.
MarketBeat · May 15 Lineage Cell Therapeutics Q1 Earnings Call Highlights Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing ma
Euronews · May 12 Roche gets European approval for Alzheimer’s diagnosis blood test Swiss pharmaceutical company Roche has received European approval for a blood test that can detect and rule out Alzheimer’s disease, offering a simpler and less invasive alternative to current diagnostic methods.
MarketBeat · May 12 Halozyme Therapeutics Q1 Earnings Call Highlights Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization. On the company’s earnings call, President and CEO
International Business Times · Dec 23, 2025 US Drug Pricing Deal May Lead to Swiss Medicine Price Hikes US drug price cuts may push up the cost of new medicines in Switzerland, Roche's CEO warns.
Benzinga · Nov 18, 2025 Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.
The Independent UK · Oct 14, 2025 Simple blood test gets green light by FDA to improve early detection of Alzheimer’s disease Millions of Americans are living with Alzheimer’s and hundreds of thousands are diagnosed each year